Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Perspective Therapeutics (CATX) Raw Materials (2017 - 2023)

Perspective Therapeutics (CATX) has disclosed Raw Materials for 11 consecutive years, with $764000.0 as the latest value for Q3 2023.

  • Quarterly Raw Materials fell 16.23% to $764000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $764000.0 through Sep 2023, down 16.23% year-over-year, with the annual reading at $752000.0 for FY2022, N/A changed from the prior year.
  • Raw Materials hit $764000.0 in Q3 2023 for Perspective Therapeutics, down from $781000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $912000.0 in Q3 2022 to a low of $330000.0 in Q3 2019.
  • Historically, Raw Materials has averaged $598105.3 across 5 years, with a median of $645000.0 in 2021.
  • Biggest five-year swings in Raw Materials: soared 98.69% in 2021 and later decreased 16.23% in 2023.
  • Year by year, Raw Materials stood at $372000.0 in 2019, then grew by 20.43% to $448000.0 in 2020, then soared by 67.63% to $751000.0 in 2021, then rose by 0.13% to $752000.0 in 2022, then rose by 1.6% to $764000.0 in 2023.
  • Business Quant data shows Raw Materials for CATX at $764000.0 in Q3 2023, $781000.0 in Q2 2023, and $777000.0 in Q1 2023.